AbbVie - Strong Product Pipeline Is Defining Its Future
- AbbVie can be considered a dividend growth stock with its dividend yield meeting Merck’s and exceeding Bristol-Myers’.
- The company is expanding operations to Asia, establishing its first manufacturing facility in Singapore with an investment figure of $320 million.
- AbbVie’s unnamed drug for Hepatitis cured 99% of the afflicted patients in a late stage study.
- Another drug, Kaletra, produced very encouraging results clearing pre-cancerous cervical lesions in 90% of treated women.